Bisognano John D, McLaughlin Trent, Roberts Craig S, Tang Simon S K
Department of Internal Medicine, Cardiology Division, University of Rochester Medical Center, New York 14642-8679, USA.
Vasc Health Risk Manag. 2007;3(5):579-85.
This retrospective database analysis compared the effectiveness of dihydropyridine calcium channel blockers (DHPs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) added to diuretics or beta-blockers. Adults with hypertension treated with diuretic or beta-blocker monotherapy between 1998 and 2001 were identified from a large US electronic medical records database of primary care practices. Patients were required to have a baseline blood pressure (BP) > or =140/90 mmHg (> or =130/80 mmHg for diabetes mellitus) and recorded BP measurements within 6 months before and 1-12 months following index date. Patients were matched 1:1:1 by propensity score to correct for differences in baseline characteristics. 1875 patients met study criteria and 660 (220 in each cohort) were matched based on propensity scores. Matched cohorts had no significant differences in baseline characteristics. Mean changes in systolic/diastolic BP were -17.5/-8.8, -15.7/-6.3, and -13.0/-8.0 mmHg with DHPs, ACE inhibitors, and ARBs, respectively. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High BP 6/7 goal attainment for each regimen was 47.3%, 40.0%, and 32.2%, respectively. DHPs, ACE inhibitors, and ARBs improved BP when added to patients' beta-blocker or diuretic therapy. The greatest benefits were observed with DHPs, followed by ACE inhibitors, then ARBs.
这项回顾性数据库分析比较了添加到利尿剂或β受体阻滞剂中的二氢吡啶类钙通道阻滞剂(DHPs)、血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂(ARBs)的有效性。从美国一个大型基层医疗实践电子病历数据库中识别出1998年至2001年间接受利尿剂或β受体阻滞剂单药治疗的成年高血压患者。患者需基线血压(BP)≥140/90 mmHg(糖尿病患者≥130/80 mmHg),并在索引日期前6个月内及索引日期后1至12个月内记录血压测量值。通过倾向评分将患者按1:1:1匹配,以校正基线特征的差异。1875名患者符合研究标准,基于倾向评分匹配了660名患者(每个队列220名)。匹配队列的基线特征无显著差异。使用DHPs、ACE抑制剂和ARBs时,收缩压/舒张压的平均变化分别为-17.5/-8.8、-15.7/-6.3和-13.0/-8.0 mmHg。每种治疗方案达到美国国家高血压预防、检测、评估和治疗联合委员会第6/7版目标的比例分别为47.3%、40.0%和32.2%。当添加到患者的β受体阻滞剂或利尿剂治疗中时,DHPs、ACE抑制剂和ARBs均可改善血压。观察到使用DHPs的获益最大,其次是ACE抑制剂,然后是ARBs。